Population-based screening in colorectal cancer - Current practice and future developments: Faecal biomarkers review

Journal of Gastrointestinal and Liver Diseases

Volumn 23, Issue 2, 2014, Pages 195-202

  Sawbridge, David ^a   Probert, Chris ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Colonoscopy; Colorectal cancer screening; CT colonography; Endoscopy; Faecal fecal occult blood; Flexible sigmoidoscopy

Indexed keywords

ALPHA ACTIN; CALGRANULIN; CARCINOEMBRYONIC ANTIGEN; DECAY ACCELERATING FACTOR; LACTOFERRIN; MINICHROMOSOME MAINTENANCE PROTEIN 2; MYC PROTEIN; OSTEOGENIN; PLACENTA PROTEIN 5; VIMENTIN; TUMOR MARKER;

ADENOMA; BARIUM ENEMA; CANCER SCREENING; CANCER STAGING; CHROMOSOME ANALYSIS; COLONOSCOPY; COLORECTAL CANCER; COMPUTED TOMOGRAPHIC COLONOGRAPHY; ENDOSCOPY; HUMAN; KIRSTEN SARCOMA ONCOVIRUS; METABOLOMICS; PERFORATION; PROTEIN DETERMINATION; QUALITY ADJUSTED LIFE YEAR; REVIEW; RISK REDUCTION; SIGMOIDOSCOPY; ADVERSE EFFECTS; CHEMISTRY; COLORECTAL NEOPLASMS; COST BENEFIT ANALYSIS; EARLY DIAGNOSIS; ECONOMICS; FECES; OCCULT BLOOD; PATIENT ATTITUDE; PROCEDURES; PROFESSIONAL PRACTICE; TRENDS;

BIOMARKERS, TUMOR; COLONOSCOPY; COLORECTAL NEOPLASMS; COST-BENEFIT ANALYSIS; EARLY DETECTION OF CANCER; FECES; HUMANS; OCCULT BLOOD; PATIENT ACCEPTANCE OF HEALTH CARE; PROFESSIONAL PRACTICE;

EID: 84901946163     PISSN: 18418724     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (97)

1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013;49:1374-1403.
2. Rees CJ, Bevan R. The National Health Service Bowel Cancer Screening Program: the early years. Expert Rev Gastroenterol Hepatol 2013;7:421-437.
3. Network NCI. Colorectal Cancer Survival by Stage. 2012. Available from http/www.ncin.org.uk/publications/data_brie_ngs/colorectal_ cancer_survival_by_stage.aspx.
4. Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988;319:525-532.
5. Tonus C, Sellinger M, Koss K, Neupert G. Faecal pyruvate kinase isoenzyme type M2 for colorectal cancer screening: a meta-analysis. World J Gastroenterol 2012;18:4004-4011.
6. Lee TJ, Rutter MD, Blanks RG, et al. Colonoscopy quality measures: experience from the NHS Bowel Cancer Screening Programme. Gut 2012;61:1050-1057.
7. Arditi C, Peytremann-Bridevaux I, Burnand B, et al. Appropriateness of colonoscopy in Europe (EPAGE II). Screening for colorectal cancer. Endoscopy 2009;41:200-208.
8. Altobelli E, Lattanzi A, Paduano R, Varassi G, di Orio F. Colorectal cancer prevention in Europe: Burden of disease and status of screening programs. Prev Med 2014;62C:132-141.
9. European Colorectal Cancer Screening Guidelines Working G, von Karsa L, Patnick J, et al. European guidelines for quality assurance in colorectal cancer screening and diagnosis: overview and introduction to the full supplement publication. Endoscopy 2013;45:51-59.
10. Winawer S, Classen M, Lambert R, et al. World Gastroenterology Organisation; International Digestive Cancer Alliance; Practice Guidelines: Colorectal cancer screening. 2007. Available from: http://www.worldgastroenterology.org/assets/downloads/en/pdf/ guidelines/06_colorectalficancer_screening.pdf.
11. Brink D, Barlow J, Bush K, et al. Institute for Clinical Systems Improvement. Colorectal Cancer Screening. 2012. Available from: https://www.icsi.org/_asset/j73fu0/Colorectal.pdf.
12. Rex DK, Johnson DA, Anderson JC, et al. American College of Gastroenterology guidelines for colorectal cancer screening 2009 [corrected]. Am J Gastroenterol 2009;104:739-750.
13. Sung JJ, Lau JY, Young GP, et al. Asia Pacific consensus recommendations for colorectal cancer screening. Gut 2008;57:1166-1176.
14. Lee BI, Hong SP, Kim SE, et al. Korean guidelines for colorectal cancer screening and polyp detection. Clin Endosc 2012;45:25-43.
15. Levin B, Lieberman DA, McFarland B, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology 2008;134:1570-1595.
16. Lieberman D. Colorectal cancer screening: practice guidelines. Dig Dis 2012;30 Suppl 2:34-38.
17. Bretthauer M. Evidence for colorectal cancer screening. Best Pract Res Clin Gastroenterol 2010;24:417-425.
18. Hewitson P, Glasziou P, Irwig L, Towler B, Watson E. Screening for colorectal cancer using the faecal occult blood test, Hemoccult. Cochrane Database Syst Rev 2007;(1):CD001216.
19. Nnoaham KE, Lines C. Modelling future capacity needs and spending on colonoscopy in the English bowel cancer screening programme. Gut 2008;57:1238-1245.
20. Tsoi KK, Ng SS, Leung MC, Sung JJ. Cost-effectiveness analysis on screening for colorectal neoplasm and management of colorectal cancer in Asia. Aliment Pharmacol Ther 2008;28:353-363.
21. Lancuck L, Patnick J, Vessey M. A cohort effect in cervical screening coverage? J Med Screen 2008;15:27-29.
22. Eilbert KW, Carroll K, Peach J, Khatoon S, Basnett I, McCulloch N. Approaches to improving breast screening uptake: evidence and experience from Tower Hamlets. Br J Cancer 2009;101 Suppl 2:S64-S67.
23. Ghanouni A, Smith SG, Halligan S, et al. Public preferences for colorectal cancer screening tests: a review of conjoint analysis studies. Expert Rev Med Dev 2013;10:489-499.
24. Dolan JG, Boohaker E, Allison J, Imperiale TF. Patients' preferences and priorities regarding colorectal cancer screening. Med Decis Making 2013;33:59-70.
25. Hawley ST, Volk RJ, Krishnamurthy P, Jibaja-Weiss M, Vernon SW, Kneuper S. Preferences for colorectal cancer screening among racially/ ethnically diverse primary care patients. Med Care 2008;46(9 Suppl 1):S10-S16.
26. Zavoral M, Suchanek S, Zavada F, et al. Colorectal cancer screening in Europe. World J Gastroenterol 2009;15:5907-5915.
27. Vart G, Banzi R, Minozzi S. Comparing participation rates between immunochemical and guaiac faecal occult blood tests: a systematic review and meta-analysis. Prev Med 2012;55:87-92.
28. Zhu MM, Xu XT, Nie F, Tong JL, Xiao SD, Ran ZH. Comparison of immunochemical and guaiac-based fecal occult blood test in screening and surveillance for advanced colorectal neoplasms: a meta-analysis. J Dig Dis 2010;11:148-160.
29. Burch JA, Soares-Weiser K, St John DJ, et al. Diagnostic accuracy of faecal occult blood tests used in screening for colorectal cancer: a systematic review. J Med Screen 2007;14:132-137.
30. Hol L, van Leerdam ME, van Ballegooijen M, et al. Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy. Gut 2010;59:62-68.
31. van Rossum LG, van Rijn AF, Laheij RJ, et al. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology 2008;135:82-90.
32. Logan RF, Patnick J, Nickerson C, et al. Outcomes of the Bowel Cancer Screening Programme (BCSP) in England after the first 1 million tests. Gut 2012;61:1439-1446.
33. Wilschut JA, Hol L, Dekker E, et al. Cost-effectiveness analysis of a quantitative immunochemical test for colorectal cancer screening. Gastroenterology 2011;141:1648-1655. e1.
34. Brenner H, Haug U, Hundt S. Sex differences in performance of fecal occult blood testing. Am J Gastroenterol 2010;105:2457-2464.
35. Mulder SA, Ouwendijk RJ, Giard RW, Van Leerdam ME, Kuipers EJ. Risk analyses for screening sigmoidoscopy based on a colorectal cancer (CRC) population. Scand J Gastroenterol 2009;44:205-210.
36. Pritchard CC, Grady WM. Colorectal cancer molecular biology moves into clinical practice. Gut 2011;60:116-129.
37. Lee TJ, Nickerson C, Goddard AF, Rees CJ, McNally RJ, Rutter MD. Outcome of 12-month surveillance colonoscopy in high-risk patients in the National Health Service Bowel Cancer Screening Programme. Colorectal Dis 2013;15:e435-e442.
38. Holme O, Bretthauer M, Fretheim A, Odgaard-Jensen J, Hoff G. Flexible sigmoidoscopy versus faecal occult blood testing for colorectal cancer screening in asymptomatic individuals. Cochrane Database Syst Rev 2013;9:CD009259.
39. Littlejohn C, Hilton S, Macfarlane GJ, Phull P. Systematic review and meta-analysis of the evidence for flexible sigmoidoscopy as a screening method for the prevention of colorectal cancer. Br J Surg 2012;99:1488-1500.
40. Martin-Lopez JE, Beltran-Calvo C, Rodriguez-Lopez R, Molina-Lopez T. Comparison of the accuracy of CT colonography and colonoscopy in the diagnosis of colorectal cancer. Colorectal Dis 2014;16:O82-O89.
41. Pickhardt PJ, Hassan C, Halligan S, Marmo R. Colorectal cancer: CT colonography and colonoscopy for detection--systematic review and meta-analysis. Radiology 2011;259:393-405.
42. Plumb AA, Halligan S, Pendse DA, Taylor SA, Mallett S. Sensitivity and specificity of CT colonography for the detection of colonic neoplasia after positive faecal occult blood testing: systematic review and metaanalysis. Eur Radiol 2014 Feb 12.
43. Dik VK, Moons LM, Siersema PD. Endoscopic innovations to increase the adenoma detection rate during colonoscopy. World J Gastroenterol 2014;20:2200-2211.
44. Selinger CP, Mullender J, Choudhury S, Jones PE, Sukumar S, Ramesh J. Flexible sigmoidoscopy does not significantly increase polyp and cancer detection yield when used to supplement CT colonography. Digestion 2012;85:55-60.
45. Schoenfeld P, Lipscomb S, Crook J, et al. Accuracy of polyp detection by gastroenterologists and nurse endoscopists during flexible sigmoidoscopy: a randomized trial. Gastroenterology 1999;117:312-318.
46. Baxter NN, Goldwasser MA, Paszat LF, Saskin R, Urbach DR, Rabeneck L. Association of colonoscopy and death from colorectal cancer. Ann Intern Med 2009;150:1-8.
47. Imperiale TF, Glowinski EA, Lin-Cooper C, Ransohoff DF. Tailoring colorectal cancer screening by considering risk of advanced proximal neoplasia. Am J Med 2012;125:1181-1187.
48. Atkin WS, Edwards R, Kralj-Hans I, et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet 2010;375:1624-1633.
49. Schoen RE, Pinsky PF, Weissfeld JL, et al. Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med 2012;366:2345-2357.
50. Weissfeld JL, Schoen RE, Pinsky PF, et al. Flexible sigmoidoscopy in the randomized prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial: added yield from a second screening examination. J Nat Cancer Inst 2012;104:280-289.
51. Tappenden P, Chilcott J, Eggington S, Patnick J, Sakai H, Karnon J. Option appraisal of population-based colorectal cancer screening programmes in England. Gut 2007;56:677-684.
52. Wilson S, Damery S, Stocken DD, et al. Serum matrix metalloproteinase 9 and colorectal neoplasia: a community-based evaluation of a potential diagnostic test. Br J Cancer 2012;106:1431-1438.
53. Mulhall BP, Veerappan GR, Jackson JL. Meta-analysis: computed tomographic colonography. Annf Intern Med 2005;142:635-650.
54. Pickhardt PJ. Incidence of colonic perforation at CT colonography: review of existing data and implications for screening of asymptomatic adults. Radiology 2006;239:313-316.
55. Pooler BD, Baumel MJ, Cash BD, et al. Screening CT colonography: multicenter survey of patient experience, preference, and potential impact on adherence. AJR Am J Roentgenol 2012;198:1361-1366.
56. Graser A, Stieber P, Nagel D, et al. Comparison of CT colonography, colonoscopy, sigmoidoscopy and faecal occult blood tests for the detection of advanced adenoma in an average risk population. Gut 2009;58:241-248.
57. de Wijkerslooth TR, de Haan MC, Stoop EM, et al. Burden of colonoscopy compared to non-cathartic CT-colonography in a colorectal cancer screening programme: randomised controlled trial. Gut 2012;61:1552-1559.
58. Albert JM. Radiation risk from CT: implications for cancer screening. AJR Am J Roentgenol 2013;201:W81-W87.
59. Berrington de Gonzalez A, Kim KP, Knudsen AB, et al. Radiation-related cancer risks from CT colonography screening: a risk-benefit analysis. AJR Am J Roentgenol 2011;196:816-823.
60. Hanly P, Skally M, Fenlon H, Sharp L. Cost-effectiveness of computed tomography colonography in colorectal cancer screening: a systematic review. Int J Technol Assess Health Care 2012;28:415-423.
61. Lee D, Muston D, Sweet A, Cunningham C, Slater A, Lock K. Cost effectiveness of CT colonography for UK NHS colorectal cancer screening of asymptomatic adults aged 60-69 years. Appl Health Econ Health Policy 2010;8:141-154.
62. NHS Cancer Screening Programmes. Guidelines for the use of imaging in the NHS Bowel Cancer Screening Programme. 2nd ed. 2012. Available from: http://www.cancerscreening.nhs.uk/bowel/ publications/nhsbcsp05.pdf
63. Regge D, Iussich G, Senore C, et al. Population screening for colorectal cancer by flexible sigmoidoscopy or CT colonography: study protocol for a multicenter randomized trial. Trials 2014;15:97.
64. Sali L, Grazzini G, Carozzi F, et al. Screening for colorectal cancer with FOBT, virtual colonoscopy and optical colonoscopy: study protocol for a randomized controlled trial in the Florence district (SAVE study). Trials 2013;14:74.
65. Strom E, Larsen JL. Colon cancer at barium enema examination and colonoscopy: a study from the county of Hordaland, Norway. Radiology 1999;211:211-214.
66. Rockey DC, Paulson E, Niedzwiecki D, et al. Analysis of air contrast barium enema, computed tomographic colonography, and colonoscopy: prospective comparison. Lancet 2005;365:305-311.
67. Yang H, Xia BQ, Jiang B, et al. Diagnostic value of stool DNA testing for multiple markers of colorectal cancer and advanced adenoma: a meta-analysis. Can J Gastroenterol 2013;27:467-475.
68. Luo YX, Chen DK, Song SX, Wang L, Wang JP. Aberrant methylation of genes in stool samples as diagnostic biomarkers for colorectal cancer or adenomas: a meta-analysis. Int J Clin Pract 2011;65:1313-1320.
69. Ahlquist DA, Zou H, Domanico M, et al. Next-generation stool DNA test accurately detects colorectal cancer and large adenomas. Gastroenterology 2012;142:248-256.
70. Itzkowitz SH, Jandorf L, Brand R, et al. Improved fecal DNA test for colorectal cancer screening. Clin Gastroenterol Hepatol 2007;5:111-117.
71. Wu GH, Wang YM, Yen AM, et al. Cost-effectiveness analysis of colorectal cancer screening with stool DNA testing in intermediateincidence countries. BMC Cancer 2006;6:136.
72. Bonfrate L, Altomare DF, Di Lena M, et al. MicroRNA in colorectal cancer: new perspectives for diagnosis, prognosis and treatment. J Gastrointestin Liver Dis 2013;22:311-320.
73. Koga Y, Yamazaki N, Yamamoto Y, et al. Fecal miR-106a is a useful marker for colorectal cancer patients with false-negative results in immunochemical fecal occult blood test. Cancer Epidemiol Biomarkers Prev 2013;22:1844-1852.
74. Koga Y, Yasunaga M, Takahashi A, et al. MicroRNA expression profiling of exfoliated colonocytes isolated from feces for colorectal cancer screening. Cancer Prev Res (Phila) 2010;3:1435-1442.
75. Kalimutho M, Del Vecchio Blanco G, Di Cecilia S, et al. Differential expression of miR-144* as a novel fecal-based diagnostic marker for colorectal cancer. J Gastroenterol 2011;46:1391-1402.
76. Mulder SA, van Leerdam ME, van Vuuren AJ, et al. Tumor pyruvate kinase isoenzyme type M2 and immunochemical fecal occult blood test: performance in screening for colorectal cancer. Eur J Gastroenterol Hepatol 2007;19:878-882.
77. Li R, Liu J, Xue H, Huang G. Diagnostic value of fecal tumor M2-pyruvate kinase for CRC screening: a systematic review and metaanalysis. Int J Cancer 2012;131:1837-1845.
78. Damms A, Bischoff SC. Validation and clinical significance of a new calprotectin rapid test for the diagnosis of gastrointestinal diseases. Int J Colorectal Dis 2008;23:985-992.
79. Meucci G, D'Inca R, Maieron R, et al. Diagnostic value of faecal calprotectin in unselected outpatients referred for colonoscopy: A multicenter prospective study. Dig Liver Dis 2010;42:191-195.
80. Yoo BC, Shin YK, Lim SB, Hong SH, Jeong SY, Park JG. Evaluation of calgranulin B in stools from the patients with colorectal cancer. Dis Colon Rectum 2008;51:1703-1709.
81. Hirata I, Hoshimoto M, Saito O, et al. Usefulness of fecal lactoferrin and hemoglobin in diagnosis of colorectal diseases. World J Gastroenterol 2007;13:1569-1574.
82. Manz M, Burri E, Rothen C, et al. Value of fecal calprotectin in the evaluation of patients with abdominal discomfort: an observational study. BMC Gastroenterol 2012;12:5.
83. Davies RJ, Freeman A, Morris LS, et al. Analysis of minichromosome maintenance proteins as a novel method for detection of colorectal cancer in stool. Lancet 2002;359:1917-1919.
84. Kim Y, Lee S, Park S, et al. Gastrointestinal tract cancer screening using fecal carcinoembryonic antigen. Ann Clin Lab Sci 2003;33:32-38.
85. Mizuno M, Mizuno M, Iwagaki N, et al. Testing of multiple samples increases the sensitivity of stool decay-accelerating factor test for the detection of colorectal cancer. Am J Gastroenterol 2003;98:2550-2555.
86. Pucci S, Bonanno E, Sesti F, et al. Clusterin in stool: a new biomarker for colon cancer screening? Am J Gastroenterol 2009;104:2807-2815.
87. Garner CE, Smith S, de Lacy Costello B, et al. Volatile organic compounds from feces and their potential for diagnosis of gastrointestinal disease. FASEB J 2007;21:1675-1688.
88. Probert CS, Ahmed I, Khalid T, Johnson E, Smith S, Ratcliffe N. Volatile organic compounds as diagnostic biomarkers in gastrointestinal and liver diseases. J Gastrointestin Liver Dis 2009;18:337-343.
89. Ahmed I, Greenwood R, Costello Bde L, Ratcliffe NM, Probert CS. An investigation of fecal volatile organic metabolites in irritable bowel syndrome. PloS One 2013;8:e58204.
90. Khalid T, Richardson P, Probert CS. The liver breath! Breath volatile organic compounds for the diagnosis of liver disease. Clin Gastroenterol Hepatol 2014;12:524-526.
91. de Meij TG, Larbi IB, van der Schee MP, et al. Electronic nose can discriminate colorectal carcinoma and advanced adenomas by fecal volatile biomarker analysis: proof of principle study. Int J Cancer 2014;134:1132-1138.
92. Monleon D, Morales JM, Barrasa A, Lopez JA, Vazquez C, Celda B. Metabolite profiling of fecal water extracts from human colorectal cancer. NMR Biomed 2009;22:342-348.
93. Sonoda H, Kohnoe S, Yamazato T, et al. Colorectal cancer screening with odour material by canine scent detection. Gut 2011;60:814-819.
94. Elliker KR, Sommerville BA, Broom DM, Neal DE, Armstrong S, Williams HC. Key considerations for the experimental training and evaluation of cancer odour detection dogs: lessons learnt from a double-blind, controlled trial of prostate cancer detection. BMC Urol 2014;14:22.
95. Cruzado J, Sanchez FI, Abellan JM, Perez-Riquelme F, Carballo F. Economic evaluation of colorectal cancer (CRC) screening. Best Pract Res Clin Gastroenterol 2013;27:867-880.
96. Ma GK, Ladabaum U. Personalizing Colorectal Cancer Screening: a Systematic Review of Models to Predict Risk of Colorectal Neoplasia. Clin Gastroenterol Hepatol 2014 Feb 15.
97. Kim DH, Cha JM, Shin HP, Joo KR, Lee JI, Park DI. Development and Validation of a Risk Stratification-based Screening Model for Predicting Colorectal Advanced Neoplasia in Korea. J Clin Gastroenterol 2014 Feb 27.